Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Obstet Gynecol ; 67(1): 169-185, 2024 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-38281174

RESUMO

Perinatal mood and anxiety disorders and substance use disorders are the primary causes of maternal mortality in the postpartum period and represent major public health concerns. Despite this, these conditions remain undertreated. Behavioral health integration in outpatient obstetric settings is necessary but insufficient to meet the needs of all patients. Inpatient behavioral health integration represents a promising avenue for addressing gaps in care. Results from recent program development indicate that needs assessment, stakeholder backing, collaboration with existing programs, and adaptability are key factors in successful implementation.


Assuntos
Pacientes Internados , Período Pós-Parto , Gravidez , Feminino , Humanos , Desenvolvimento de Programas , Afeto , Mortalidade Materna
2.
Clin Obstet Gynecol ; 67(1): 186-199, 2024 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-38281175

RESUMO

Perinatal mental health conditions are the most common complications of childbirth and have well-established enduring negative effects. Obstetric (Ob) clinicians care for patients with perinatal mental health conditions across a spectrum of acuity, severity, and complexity. Ob and psychiatric clinicians can collaborate to create a cohesive continuum of psychopharmacologic care for perinatal patients. This chapter provides an overall framework for Ob-psychiatric clinician collaboration with examples of innovation in care delivery.


Assuntos
Transtornos Mentais , Psicofarmacologia , Gravidez , Feminino , Criança , Recém-Nascido , Humanos , Transtornos Mentais/tratamento farmacológico , Assistência Perinatal , Atenção à Saúde , Saúde Mental
5.
Curr Psychiatry Rep ; 24(11): 687-695, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36181572

RESUMO

PURPOSE OF REVIEW: To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy. RECENT FINDINGS: Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders. Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.


Assuntos
Complicações na Gravidez , Efeitos Tardios da Exposição Pré-Natal , Criança , Feminino , Humanos , Recém-Nascido , Gravidez , Feto , Mães , Complicações na Gravidez/tratamento farmacológico , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA